Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:IMDX NASDAQ:JMAC NASDAQ:TCRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.01-0.5%$2.55$1.29▼$3.23$191M2.74426,307 shs161,952 shsIMDXOncocyte$5.38+0.2%$5.20$2.33▼$8.51$173.40M1.79272,659 shs313,437 shsJMACMaxpro Capital Acquisition$20.09-12.0%$14.55$7.50▼$19.22$269.77M0.0174,040 shs21,844 shsTCRTAlaunos Therapeutics$2.15$2.52$1.67▼$6.20$52.51M-1.0719,401 shs2,411 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen-0.50%+1.01%-28.21%-2.43%+18.24%IMDXOncocyte+0.19%+1.13%-11.66%+30.90%+537,999,900.00%JMACMaxpro Capital Acquisition-12.00%+38.64%+42.63%+12.42%+252.77%TCRTAlaunos Therapeutics0.00%-3.15%-11.16%-28.57%-56.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.01-0.5%$2.55$1.29▼$3.23$191M2.74426,307 shs161,952 shsIMDXOncocyte$5.38+0.2%$5.20$2.33▼$8.51$173.40M1.79272,659 shs313,437 shsJMACMaxpro Capital Acquisition$20.09-12.0%$14.55$7.50▼$19.22$269.77M0.0174,040 shs21,844 shsTCRTAlaunos Therapeutics$2.15$2.52$1.67▼$6.20$52.51M-1.0719,401 shs2,411 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen-0.50%+1.01%-28.21%-2.43%+18.24%IMDXOncocyte+0.19%+1.13%-11.66%+30.90%+537,999,900.00%JMACMaxpro Capital Acquisition-12.00%+38.64%+42.63%+12.42%+252.77%TCRTAlaunos Therapeutics0.00%-3.15%-11.16%-28.57%-56.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 2.80Moderate Buy$5.00148.76% UpsideIMDXOncocyte 2.00Hold$12.00123.05% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/ATCRTAlaunos Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest TCRT, IMDX, CGEN, and JMAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/21/2026CGENCompugen Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $5.005/15/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026CGENCompugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026CGENCompugen Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.003/27/2026IMDXOncocyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/25/2026CGENCompugen Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$72.76M2.61$0.37 per share5.41$1.09 per share1.84IMDXOncocyte$4.05M42.89N/AN/A($1.10) per share-4.89JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/A$0.93 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen$35.34M$0.375.43N/AN/A47.97%47.72%27.51%8/5/2026 (Estimated)IMDXOncocyte-$50.22M-$1.48N/AN/AN/A-2,454.64%N/A-96.96%N/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AN/ATCRTAlaunos Therapeutics-$4.18M-$2.13N/AN/AN/AN/A-165.94%-123.50%8/18/2026 (Estimated)Latest TCRT, IMDX, CGEN, and JMAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CGENCompugen-$0.07-$0.08-$0.01-$0.08$1.57 million$2.18 million5/15/2026Q1 2026TCRTAlaunos TherapeuticsN/A-$0.59N/A-$0.59N/AN/A5/13/2026Q1 2026IMDXOncocyteN/A-$0.28N/A-$0.12N/A$0.03 million3/31/2026Q4 2025TCRTAlaunos TherapeuticsN/A-$0.36N/A-$0.36N/A$0.00 million3/26/2026Q4 2025IMDXOncocyteN/A-$0.27N/A-$0.72N/A$1.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AIMDXOncocyteN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A6.236.23IMDXOncocyteN/A2.542.51JMACMaxpro Capital AcquisitionN/AN/AN/ATCRTAlaunos TherapeuticsN/A1.631.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%IMDXOncocyte55.35%JMACMaxpro Capital Acquisition73.18%TCRTAlaunos Therapeutics27.72%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%IMDXOncocyte2.21%JMACMaxpro Capital Acquisition19.27%TCRTAlaunos Therapeutics16.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7094.55 million85.57 millionOptionableIMDXOncocyte12032.29 million31.58 millionN/AJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableTCRTAlaunos Therapeutics4024.42 million20.48 millionNo DataTCRT, IMDX, CGEN, and JMAC HeadlinesRecent News About These CompaniesAlaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesMay 26, 2026 | finanznachrichten.deAlaunos reports positive preclinical obesity drug results across weight, liver, insulin markersMay 26, 2026 | msn.comAlaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesMay 26, 2026 | globenewswire.comAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity ModelsMay 18, 2026 | globenewswire.comWeight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares DropMarch 2, 2026 | benzinga.comAlaunos Reports Positive Preclinical Data for Obesity CandidateMarch 2, 2026 | tipranks.comAlaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic DisordersMarch 2, 2026 | globenewswire.comAlaunos Therapeutics Reaches Settlement With MD Anderson CancerDecember 23, 2025 | tipranks.comAlaunos Therapeutics files to sell 327,740 shares of common for holdersOctober 22, 2025 | msn.comAlaunos Therapeutics files $50M mixed securities shelfAugust 21, 2025 | msn.comAlaunos Therapeutics files $50M mixed securities shelfAugust 21, 2025 | msn.comAlaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market ImplicationsAugust 12, 2025 | msn.comAlaunos Therapeutics Appoints Holger Weis as New CEOJuly 25, 2025 | theglobeandmail.comAlaunos Therapeutics Taps Board Member Weis as Next CEOJuly 2, 2025 | marketwatch.comAlaunos Therapeutics, Inc. (TCRT) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comAlaunos Therapeutics Raises $850,000 in Private OfferingJune 26, 2025 | tipranks.comAlaunos Therapeutics Announces $2.0 Million Registered Direct Offering - MorningstarJune 24, 2025 | morningstar.comMAlaunos Therapeutics Announces $2.0 Million Registered Direct OfferingJune 23, 2025 | globenewswire.comAlaunos Therapeutics Amends Warrant Agreement with Mast HillJune 10, 2025 | tipranks.comPMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)May 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCRT, IMDX, CGEN, and JMAC Company DescriptionsCompugen NASDAQ:CGEN$2.01 -0.01 (-0.50%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$2.00 0.00 (-0.25%) As of 06/24/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Oncocyte NASDAQ:IMDX$5.38 +0.01 (+0.19%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$5.41 +0.03 (+0.56%) As of 06/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Maxpro Capital Acquisition NASDAQ:JMAC$20.09 -2.74 (-12.00%) As of 06/23/2026Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Alaunos Therapeutics NASDAQ:TCRT$2.15 0.00 (0.00%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$2.15 +0.00 (+0.23%) As of 06/24/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
